Trans-C75

• Description:

  Trans-C75 ((±) -C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.

• Product Name Alternative:

  (±) -C75

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Fatty Acid Synthase (FASN)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/C75-trans.html

• Concentration:

  10mM

• Purity:

  99.79

• Solubility:

  DMSO : 83.3 mg/mL (ultrasonic; warming)

• Smiles:

  O=C([C@@H](C1=C)[C@@H](CCCCCCCC)OC1=O)O

• Molecular Formula:

  C14H22O4

• Molecular Weight:

  254.33

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.|[2]Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+) -C75 is a strong anorectic drug; (-) -C75 has antitumor activity. Chirality. 2013 May;25 (5) :281-7.|[3]Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100 (10) :5628-33.|[4]Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99 (14) :9498-502.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [191282-48-1]